Clinical Scorecard: Diabetes Rates and Management Among Adults in the United States
At a Glance
Category
Detail
Condition
Claims-coded diabetes, hyperglycemia, and hypoglycemia
Key Mechanisms
Mechanisms or clinical associations described in the source article.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
Age- and sex-adjusted diagnosed diabetes prevalence increased from 8.99% in 2018 to 10.61% in 2024.
Among people with diagnosed diabetes, coded hyperglycemia increased from 33.96% to 37.32%; coded hypoglycemia changed little.
Diabetes prevalence increased over time in every state, with substantial geographic variation.
Commercially insured enrollees had lower diabetes prevalence than Medicaid managed care and Medicare Advantage enrollees but the fastest increase.
Claims-based estimates reflect diagnosed conditions, not true prevalence, and may be affected by screening, billing practices, and changes in dataset composition.
Guideline-Based Recommendations
Diagnosis
The study identified diabetes using at least 2 outpatient diagnoses recorded more than 7 days apart or 1 inpatient diagnosis, using ICD-10 codes E8 to E11 or E13.
Management
The study did not report treatment or management recommendations.
Monitoring & Follow-up
The authors state that linked data may have an important role in detecting geographic hot spots.
Risks
Claims estimates capture diagnosed diabetes, not true prevalence; trends may partly reflect changes in detection.
Differences in screening and billing practices may contribute to variation in coded hyperglycemia.
Removal of one commercial insurance plan in 2024 reduced sample sizes in several states and may affect state comparisons.
Patient & Prescribing Data
The analysis included 285,213,216 person-years among adults aged 18 to 64 years; median age was 41 years and 54.8% were female.
The article reports prevalence of coded diagnoses and does not provide treatment or prescribing data.
Clinical Best Practices
The study measures prevalence of claims-coded diagnoses, not true diabetes prevalence.
The authors report geographic and insurance-group differences and note potential variation in screening, billing, and dataset composition.
The study does not provide clinical treatment recommendations.
